Dry Age-Related Macular Degeneration Market-Forecast till 2027

Dry Age-Related Macular Degeneration Market-Forecast till 2027

$4450 – $6250

According to this report, the global dry age-related macular degeneration market is to witness a CAGR of 8.62% during the review period to surpass USD 6,113.33 million by 2027.

SKU: MRFR210210 Category: Tag:

Description

Dry Age-Related Macular Degeneration Market-Forecast till 2027

Dry Age-Related Macular Degeneration Market Forecast

According to this report, the global dry age-related macular degeneration market is projected to witness a significant CAGR of 8.62% during the review period to surpass USD 6,113.33 million by the end of 2027. Dry macular degeneration is a typical eye issue among individuals aged more than 50. The macula is the piece of the retina answerable for clear vision in your immediate view.

The development of the worldwide dry Age-related Macular Degeneration market is ascribed to the developing geriatric populace and expanding pervasiveness old enough related macular degeneration, and the presentation of novel treatment techniques for dry AMD combined with the expanding number of clinical preliminaries zeroed in on dry AMD.

Different variables like expanding medical services use are probably going to assist the market with developing. In any case, a large number of bombed clinical preliminaries for dry AMD medications may hamper the market development somewhat. The global market expansion is propelled by the growing geriatric population and rising incidences of dry age-related macular degeneration.

Segment Overview

The global dry age-related macular degeneration AMD market has been divided based on stages, age group, route of administration, diagnosis & treatment, and end-user.

Based on Stages the global market has been classified into Early stage of AMD, Intermediate Stage of AMD, and Late Stage of AMD.

By age group segment, the global market is categorized into above 75 years, above 60 years, and above 40 years.

In terms of diagnosis & treatment, the dry age-related macular degeneration AMD market is bifurcated into treatment and diagnosis.

The treatment is further classified into nutrition therapy and telescopic lens implant. The nutrition therapy segment is sub-segmented into antioxidants and others. Based on the route of administration, the market is divided into oral and injectables.

In terms of end-user, the market is categorized into hospitals &clinics, diagnostic centers, academic &research institutes, and others.

Regional Analysis

Based on region, the global dry AMD market has been classified into North America, Europe, Asia-Pacific, and the Rest of the World.

North America is likely to drive the largest market for global dry AMD owing to the government initiatives and funding in the region. Europe holds the second biggest portion of the overall industry because of the expanding more seasoned populace and rising patient populace.

Furthermore, further developing government drives, expanding medical care casings, and rising interest for mechanically inventive therapy are driving the development of the dry age-related macular degeneration market in Europe. The Asia-Pacific exhibits the rapidly developing business sector for age-related macular degeneration as it is creating at an exceptionally fast speed and has shown the rise of numerous players.

Major Players

Major players of the global dry age-related macular degeneration market are Santen Pharmaceuticals Inc. (Japan), Allergan plc (Ireland), Bausch Health (Canada), Alimera Science Inc. (US), Phio Pharmaceuticals Corp (US), Ocumension Therapeutics Co. Ltd (China), Belite Bio Inc. (US), Kubota Vision Inc. (US), Iveric Bio (US), Eyestem Research Pvt Ltd (India), Yuyang DNU Co., Ltd (South Korea), and Stealth Biotherapeutics Inc. (US)

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.

Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Global Healthcare Consulting Services Market -Forecast till 2027

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENTS 1 EXECUTIVE SUMMARY 2 MARKET INTRODUCTION 2.1 SCOPE OF THE STUDY 2.2 RESEARCH OBJECTIVE 2.3 MARKET STRUCTURE 2.4 ASSUMPTIONS & LIMITATIONS 3 RESEARCH METHODOLOGY 3.1 DATA MINING 3.2 SECONDARY RESEARCH 3.3 PRIMARY RESEARCH 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 3.5 FORECASTING TECHNIQUES 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 3.6.1 BOTTOM-UP APPROACH 3.6.2 TOP-DOWN APPROACH 3.7 DATA TRIANGULATION 3.8 VALIDATION 4 MARKET DYNAMICS 4.1 OVERVIEW 4.2 DRIVERS 4.2.1 GROWING GERIATRIC POPULATION AND INCREASING PREVALENCE OF DRY AGE-RELATED MACULAR DEGENERATION 4.2.2 INCREASING HEALTHCARE EXPENDITURE 4.3 RESTRAINTS 4.3.1 FAILED CLINICAL TRAILS FOR DRY AMD 4.4 OPPORTUNITIES 4.4.1 INCREASE IN PIPELINE DRUGS FOR DRY AMD 4.4.2 DEVELOPMENT OF NEW TECHNOLOGIES FOR TREATMENT 4.5 EPIDEMIOLOGY OF DRY AMD 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 5.1.1 R&D 5.1.2 MANUFACTURING 5.1.3 DISTRIBUTION AND SALES 5.1.4 POST-SALES MONITORING 5.2 PORTER'S FIVE FORCES MODEL 5.2.1 BARGAINING POWER OF SUPPLIERS 5.2.2 BARGAINING POWER OF BUYERS 5.2.3 THREAT OF NEW ENTRANTS 5.2.4 THREAT OF SUBSTITUTES 5.2.5 INTENSITY OF RIVALRY 5.3 IMPACT OF COVID-19 ON THE DRY AMD MARKET 5.3.1 OVERVIEW 5.3.2 IMPACT ON PATIENTS WITH DRY AMD 5.3.3 IMPACT ON CLINICAL TRIALS 5.3.4 IMPACT ON R&D 5.3.5 IMPACT ON MARKET GROWTH 6 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES 6.1 OVERVIEW 6.2 EARLY AGE-RELATED MACULAR DEGENERATION 6.3 INTERMEDIATE AGE-RELATED MACULAR DEGENERATION 6.4 LATE AGE-RELATED MACULAR DEGENERATION 7 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP 7.1 OVERVIEW 7.2 ABOVE 40 YEARS 7.3 ABOVE 60 YEARS 7.4 ABOVE 75 YEARS 8 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT 8.1 OVERVIEW 8.2 TREATMENT 8.3 DIAGNOSIS 9 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 9.1 OVERVIEW 9.2 ORAL 9.3 INJECTABLES 10 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 10.1 OVERVIEW 10.2 HOSPITAL & CLINICS 10.3 DIAGNOSTIC CENTERS 10.4 ACADEMIC RESEARCH INSTITUTES 10.5 OTHERS 11 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION 11.1 OVERVIEW 11.2 NORTH AMERICA 11.2.1 US 11.2.2 CANADA 11.3 EUROPE 11.3.1 GERMANY 11.3.2 UK 11.3.3 FRANCE 11.3.4 ITALY 11.3.5 SPAIN 11.3.6 REST OF EUROPE 11.4 ASIA-PACIFIC 11.4.1 CHINA 11.4.2 JAPAN 11.4.3 INDIA 11.4.4 SOUTH KOREA 11.4.5 AUSTRALIA 11.4.6 REST OF ASIA-PACIFIC 11.5 REST OF THE WORLD 11.5.1 MIDDLE EAST 11.5.2 AFRICA 11.5.3 LATIN AMERICA 12 COMPETITIVE LANDSCAPE 12.1 COMPETITIVEOVERVIEW 12.2 MARKET SHARE ANALYSIS 12.3 MAJOR GROWTH STRATEGIES IN THE GLOBAL DRY AMD MARKET 12.4 COMPETITIVE BENCHMARKING 12.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL DRY AMD MARKET 12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 12.6.1 CONTRACTS & AGREEMENTS 12.6.2 NEW PRODUCT DEVELOPMENTS/LAUNCHES 12.6.3 COLLABORATIONS/ EXPANSIONS/PARTNERSHIPS/JOINT VENTURES 12.6.4 INVESTMENT 12.7 MAJOR PLAYERS FINANCIAL MATRIX 12.7.1 SALES, 2020 12.7.2 R&D EXPENDITURE, 2020 13 COMPANY PROFILES 13.1 SANTEN PHARMACEUTICALS INC. 13.1.1 COMPANY OVERVIEW 13.1.2 FINANCIAL OVERVIEW 13.1.3 PRODUCTS/SERVICES OFFERED 13.1.4 KEY DEVELOPMENTS 13.1.5 SWOT ANALYSIS 13.1.6 KEY STRATEGIES 13.2 ALLERGAN PLC 13.2.1 COMPANY OVERVIEW 13.2.2 FINANCIAL OVERVIEW 13.2.3 PRODUCTS/SERVICES OFFERED 13.2.4 ALLERGAN: KEY DEVELOPMENTS 13.2.5 SWOT ANALYSIS 13.2.6 KEY STRATEGIES 13.3 BAUSCH HEALTH (VALEANT PHARMACEUTICALS) 13.3.1 COMPANY OVERVIEW 13.3.2 FINANCIAL OVERVIEW 13.3.3 PRODUCTS/SERVICES OFFERED 13.3.4 KEY DEVELOPMENTS 13.3.5 SWOT ANALYSIS 13.3.6 KEY STRATEGIES 13.4 ALIMERA SCIENCES INC. 13.4.1 COMPANY OVERVIEWS 13.4.2 FINANCIAL OVERVIEW 13.4.3 PRODUCTS/SERVICES OFFERED 13.4.4 KEY DEVELOPMENTS 13.4.5 SWOT ANALYSIS 13.4.6 KEY STRATEGIES 13.5 RXI PHARMACEUTICALS, INC. (PHIO PHARMACEUTICALS CORP) 13.5.1 COMPANY OVERVIEW 13.5.2 FINANCIAL OVERVIEW 13.5.3 PRODUCTS/SERVICES OFFERED 13.5.4 KEY DEVELOPMENTS 13.5.5 SWOT ANALYSIS 13.5.6 KEY STRATEGIES 13.6 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD 13.6.1 COMPANY OVERVIEWS 13.6.2 FINANCIAL OVERVIEW 13.6.3 PRODUCTS/SERVICES OFFERED 13.6.4 KEY DEVELOPMENTS 13.6.5 SWOT ANALYSIS 13.6.6 KEY STRATEGIES 13.7 BELITE BIO INC. 13.7.1 COMPANY OVERVIEW 13.7.2 FINANCIAL OVERVIEW 13.7.3 PRODUCTS/SERVICES OFFERED 13.7.4 KEY DEVELOPMENTS 13.7.5 SWOT ANALYSIS 13.7.6 KEY STRATEGIES 13.8 KUBOTA VISION INC. 13.8.1 COMPANY OVERVIEW 13.8.2 FINANCIAL OVERVIEW 13.8.3 PRODUCTS/SERVICES OFFERED 13.8.4 KEY DEVELOPMENTS 13.8.5 SWOT ANALYSIS 13.8.6 KEY STRATEGIES 13.9 IVERIC BIO 13.9.1 COMPANY OVERVIEW 13.9.2 FINANCIAL OVERVIEW 13.9.3 PRODUCTS/SERVICES OFFERED 13.9.4 KEY DEVELOPMENTS 13.9.5 SWOT ANALYSIS 13.9.6 KEY STRATEGIES 13.10 EYESTEM RESEARCH PVT LTD 13.10.1 COMPANY OVERVIEW 13.10.2 FINANCIAL OVERVIEW 13.10.3 PRODUCTS/SERVICES OFFERED 13.10.4 KEY DEVELOPMENTS 13.10.5 SWOT ANALYSIS 13.10.6 KEY STRATEGIES 13.11 YUYANG DNU CO., LTD 13.11.1 COMPANY OVERVIEW 13.11.2 FINANCIAL OVERVIEW 13.11.3 PRODUCTS/SERVICES OFFERED 13.11.4 KEY DEVELOPMENTS 13.11.5 SWOT ANALYSIS 13.11.6 KEY STRATEGIES 13.12 STEALTH BIOTHERAPEUTICS CORP 13.12.1 COMPANY OVERVIEW 13.12.2 FINANCIAL OVERVIEW 13.12.3 PRODUCTS/SERVICES OFFERED 13.12.4 KEY DEVELOPMENTS 13.12.5 SWOT ANALYSIS 13.12.6 KEY STRATEGIES 14 APPENDIX 14.1 REFERENCES 14.2 RELATED REPORTS

Related products